Takeda Pharmaceutical Company Limited announced the signing of a framework agreement to acquire a range of over-the-counter (OTC) medicines and food supplements, assuming fulfillment of certain conditions, from Unipharm Inc. (Unipharm), a specialist healthcare company headquartered in New York, USA.
These products are for promotion and sale primarily in Russia, where Takeda has a strong presence providing innovative medicines, primary care medicines and OTC products to its people and patients. The portfolio is a strong strategic fit with Takeda’s Russian OTC business.
“This agreement demonstrates Takeda’s commitment to better health for patients across Emerging Markets with a range of trusted and proven products” commented Ricardo Marek, President, Emerging Markets Business Unit of Takeda.
Russia is a key country for Takeda’s Emerging Markets business. Takeda Russia delivered underlying revenue growth of over 20% in the first half of 2017, and is one of the fastest growing companies locally. The products in scope are highly synergistic with our existing OTC business and will further strengthen our top 10 position in Russia, where a significant portion of the pharmaceutical market is retail.
The framework agreement, which has been signed by Takeda Pharmaceuticals International AG, includes the rights for a number of Unipharm’s OTC products such as Vitrum (supplement), Artra (pain relief) and Melaxen (sleeping agent). Takeda expects the remaining conditions of this deal to be completed during 2018.